Company intelligence / Profile preview
Talus Bioscience
Seattle, Washington, USAtalus.bio ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Talus Bioscience is generating first-in-class small molecules against previously undruggable transcription factors and other gene regulators in oncology and related indications, using their proprietary MARMOT platform for in-cell chemoproteomics and AI-powered drug design. Several programs are underway, all at preclinical stage, with first-in-class progress against previously unreachable targets[1][4][6].
- Therapeutic areas
- OncologyImmunologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Talus Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Talus Bioscience.